INTRODUCTION
============

Bladder cancer (BC) is one of the leading causes of cancer-related death worldwide, with an estimated 429,800 new cases and 165,100 deaths globally in 2012 \[[@B1]\]. BCs can be categorized into 2 groups: nonmuscle invasive BC (NMIBC) and muscle invasive BC (MIBC). Approximately 70% to 80% of patients are diagnosed with NMIBC, and some of these patients have a high risk of recurrence and a variable risk of progression despite administration of local therapies \[[@B2]\]. The remaining 25% of patients with MIBC are managed by radical surgery or radiotherapy, but often still have poor outcomes, despite administration of these systemic therapies \[[@B2]\]. For patients with advanced BC or failure of first-line chemotherapy, no clearly defined second-line treatments have been shown to prolong overall survival \[[@B2]\]. Therefore, elucidation of novel molecular mechanisms of BC progression and identification of novel tumor markers that can predict recurrence or survival are urgently needed.

Despite its relatively low sensitivity (30%--40%), urinary cytology is a reliable marker for BC diagnosis because of its high specificity (90%--95%). However, because of the low sensitivity of urinary cytology, patients are still forced to undergo a painful cystoscopic procedure to confirm the initial diagnosis and to check for recurrence during follow-up examinations after undergoing transurethral resection of bladder tumors. Several new urine-based tests for BC, such as bladder tumor antigen, nuclear matrix protein 22 (NMP22, Sysmex Corp., Kobe, Japan), and FISH (UroVysion, Abbott Molecular Inc, Des Plaines, IL, USA), have been approved for clinical use. However, these new urinary markers have not been widely applied because they have relatively low specificities (60%--80%) compared with urinary cytology, despite their higher sensitivities (50%--70%) \[[@B3]\]. Thus, specificity may come at the cost of sensitivity, and conventional urinary cytology is a good example of this compromise. Accordingly, new effective diagnostic markers are urgently needed for patients with BC.

MicroRNAs (miRNAs) are endogenous small noncoding RNA molecules (19--22 bases in length) that negatively regulate the expression of protein-coding genes in a sequence-specific manner \[[@B4]\]. The nature of miRNAs is unique in that one miRNA can regulate multiple protein-coding RNAs. Bioinformatics predictions have indicated that miRNAs regulate 30% to 60% of the protein-coding genes in the human genome \[[@B5][@B6]\]. Growing evidence has demonstrated that aberrantly expressed miRNAs can act as oncogenes or tumor suppressors in various types of malignancies \[[@B7]\]. These miRNAs can disrupt tightly controlled RNA networks in cancer cells \[[@B8]\]. Since 2006, we have rigorously investigated the molecular networks of miRNAs and their target genes in clinical BC. Identification of aberrantly expressed miRNAs in BC could provide important clues for the investigation of novel molecular mechanisms of initiation, progression, and metastasis in BC. In this review, we discuss the role of miRNAs in BC on the basis of up-to-date results from our laboratory and other research groups.

CURRENT CONSENSUS OF EPIGENETIC GENE REGULATION BY NONCODING RNA
================================================================

After the completion of the Human Genome Project in 2003, about 20,000 to 25,000 genes were identified, and the sequences of 3 billion base pairs of human DNA were determined \[[@B9]\]. Surprisingly, only 2% of the human genome encodes functional proteins; 50% to 75% of the human genome is transcribed, and 98% of the transcripts are not translated into protein. [Fig. 1](#F1){ref-type="fig"} shows the current consensus of epigenetic regulation by noncoding RNAs transcribed from approximately 70% of the genomic region that used to be considered as \"junk DNA\" \[[@B10]\]. These noncoding RNAs can be roughly classified into two groups according to size. The first group includes short RNAs of less than 200 nucleotides (nt) in length; miRNAs, which are small RNA molecules of around 18 to 22 nt in length, fit into this group, as do other classes of small RNAs, such as piwi-interacting RNAs (around 23--30 nt) \[[@B11]\]. The other group includes long noncoding RNAs (lncRNAs) of around 200 nt or more. lncRNAs have been implicated in a range of developmental processes and diseases and can inhibit or activate gene expression through a range of diverse mechanisms. In contrast to miRNAs, which have been extensively studied and have well-understood functions in gene regulation, lncRNAs are not well studied or characterized.

MICRORNAS BIOGENESIS
====================

miRNAs are evolutionarily conserved and are located either within the introns or exons of protein-coding genes (70%) or in intergenic regions (30%). Most intronic and exonic miRNAs are derived from their host genes, which suggests that they are transcribed concurrently with their host transcripts. Transcripts containing primary miRNAs (pri-miRNAs), which can vary from 200 nt to several kb in length, are capped with a specially modified nucleotide at the 5\'-terminus and are polyadenylated with multiple adenosines at the 3\'-end. Pri-miRNA is cleaved into precursor-miRNA (pre-miRNA: 60--70 nt in length) by the RNAse III enzyme (also known as Drosha). Pre-miRNA is exported from the nucleus into the cytoplasm by exportin-5. In the cytoplasm, pre-miRNA is cleaved by another RNase III enzyme, known as Dicer, into miRNA duplexes of approximately 19--22 nt in length. One miRNA duplex is then recruited into the RNA-induced silencing complex and functions to recognize complementary sites within the target messenger RNA (mRNA), thereby regulating translation through mRNA cleavage, degradation, or transcriptional repression \[[@B12]\].

MICRORNA PROFILING STUDIES IN BLADDER CANCER
============================================

miRNA expression profiling by array-based and polymerase chain reaction (PCR)-based methods is not commonly used because these methods only allow for identification of a limited number of known miRNAs. The rapid development of high-throughput, deep sequencing (DS) technology has provided novel information regarding the functions and features of miRNAs. Han et al. \[[@B13]\] first reported miRNA profiling in BC by using an Illumina Genome Analyzer IIX in 2011. Soon thereafter, five studies used DS technology to establish the miRNA profiles of clinical BC samples \[[@B14][@B15][@B16][@B17][@B18]\]. To date, the largest DS study on BC is a comprehensive investigation by The Cancer Genome Atlas Research Network \[[@B18]\]. Tissues from 131 patients with high-grade MIBC were analyzed by RNA sequencing together with 118 blood samples from the same individuals and 23 adjacent histologically proven normal tissues. The aim of the project was to carry out genetic and epigenetic characterization of the molecular landscape of high-grade MIBC. In our studies, we conducted miRNA profiling by use of both PCRbased methods and DS technology \[[@B17][@B19]\]. When comparing our 2 studies, the altered expression of miRNAs detected by DS technology was very similar to the results of PCRbased methods. In addition, a considerable number of novel miRNAs have been reported by some studies \[[@B13][@B14][@B17]\]. Therefore, this analysis supports that DS technology is superior to previously used methods. Although PCR-based and DS profiles are not comparable from a quantitative point of view, sequencing approaches should provide substantial improvements to transcriptome analyses.

MOLECULAR TARGETS OF MICRORNAS IN BLADDER CANCER
================================================

1. Features of miRNA studies in BC
----------------------------------

Growing evidence has demonstrated that aberrantly expressed miRNAs can act as oncogenic miRNAs (oncomiRNAs) or tumor-suppressive miRNAs (TS-miRNAs) in BC \[[@B12][@B20]\]. Because miRNAs can construct miRNA-target gene networks that contribute to tumor initiation, survival, and invasion, many investigators have focused on the genes targeted by aberrantly expressed miRNAs in BC in comparison with normal bladder epithelium. In terms of miRNA analysis, luciferase-reporter assays are useful for confirming the direct binding of miRNAs to the specific 3\'-untranslated region of the mRNA representing the target gene. Hence, we have summarized the miRNA studies in BC for which the target genes were validated by luciferase-reporter assays. To date, we have identified 78 studies that satisfied our criteria ([Tables 1](#T1){ref-type="table"} and [2](#T2){ref-type="table"}). As shown in [Table 1](#T1){ref-type="table"}, several TS-miRNAs, including *miR-1*, *miR-16*, *miR-24*, *miR-101*, *miR-125b*, *miR-129*, and *miR-133a*, have been shown to be located on different chromosomal regions but to have common sequences in their mature miRNAs. This suggests that the expression of these TS-miRNAs may be maintained by another genomic region, even though one region may be functionally disordered because of methylation, deletion, or mutation. This type of backup system is thought to have important roles in protecting normal cells from carcinogenesis.

The miRNAs in [Table 1](#T1){ref-type="table"} are listed in order of miRNA number, and the validated target genes are indicated. Interestingly, among the 54 miRNAs examined, 45 were downregulated, whereas 9 were upregulated. In our experience, we often encountered difficulties with the use of anti-miRNAs in in vitro studies; however, miRNA restoration systems using miRNA transfection are well established and commercially available. Accordingly, the latter system may be easier to use to examine the potential tumor-suppressive roles of the downregulated miRNAs.

miRNAs have been shown to regulate target gene expression. Several miRNAs and their targets have been identified in BC ([Table 2](#T2){ref-type="table"}). Among the 61 target genes examined, the expression levels in clinical BC specimens compared with the levels in normal bladder epithelium were validated for 40 genes. The downregulation of several miRNAs, including *miR-1*, *miR-133a*, *miR-145*, *miR-195*, and the *miR-200* family, has been reported, and these miRNAs have been shown to be involved in crucial cellular processes, such as the epithelial-mesenchymal transition (EMT), cell cycle, apoptosis, and cancer signaling pathways. TS-miRNAs and their target genes were classified into functional annotations by using the Kyoto Encyclopedia of Genes and Genomes pathways ([Table 2](#T2){ref-type="table"}).

2. Clustered miRNAs
-------------------

Several miRNAs are located in close proximity (within 10 kbp) in the same genomic region; this is called a miRNA cluster. Because of their simultaneous expression, common target genes of miRNAs within a cluster may be important for tumor biology. For example, *miR-145* forms a cluster with *miR-143* on chromosome 5q32, and these clustered miRNAs are regulated by a common promoter \[[@B21]\]. Research indicates that both *miR-145* and *miR-143* are frequently downregulated in a broad range of cancers, including BC. Villadsen et al. \[[@B22]\] suggested that *SERPINE1* is a direct target of both *miR-145* and *miR-143*; this was the first report of an miRNA cluster targeting the same mRNA in BC. Importantly, *miR-145* has been implicated in the p53 regulatory network in human malignancies \[[@B23]\]. p53 transcriptionally induces the expression of *miR-145* by interaction with a potential p53 response element in the *miR-145* promoter; moreover, *MYC* is directly repressed by *miR-145*. Additionally, Chiyomaru et al. \[[@B24]\] found direct binding of the *miR-23b/27b* cluster with *EGFR/MET*, and Itesako et al. \[[@B17]\] found direct binding of the *miR-195/497* cluster with *BIRC5*, which encodes survivin.

3. Cell cycle/apoptosis-related genes
-------------------------------------

Avoidance of apoptosis and cell cycle acceleration are required for cancer cells to escape cell death. *BCL2L2*, a member of the BCL2 family, can promote cell survival by inhibiting the intrinsic pathway of apoptosis. In contrast, *BIRC5* (*survivin*) is a key member of the inhibitor of apoptosis protein family. Several TS-miRNAs induce apoptosis through targeting *BCL2L2* (*miR-133b*, *miR-203*) and *BIRC5* (*miR-195*, *miR-203*, *miR-497*). Upregulation of *miR-129* may be involved in avoidance of apoptosis through direct targeting of *SOX4* and *GALNT1*, which are involved in transcription and protein expression, respectively \[[@B25]\]. One important pathway is the sequential activation of caspases, which have a central role in the execution of cell apoptosis. *miR-1* is downregulated in both clinical BC tissues and cultured BC cells and has been shown to induce apoptosis by increasing the activity of caspases 3 and 7 through direct targeting of the apoptosis inhibitor *SRSF9* \[[@B26]\]. Additionally, *CASP2* (caspase 2) is directly targeted by an onco-miRNA, *miR-706* \[[@B27]\].

Several miRNAs have been shown to control the cell cycle through their target genes. Matsushita et al. \[[@B28]\] first reported that cell-cycle-related genes, such as *CCNE1/2*, *CDC25A*, and *PKMYT1*, are directly regulated by *miR-144-5p*. *CDC25A* is also regulated by *miR-449a*, and *CDK4* and *CDK6* are regulated by *miR-124-3p*, *miR-195*, *miR-29c*, *miR-230c*, and *miR-449a*, inducing G~1~-phase arrest. Interestingly, *miR-96*, which is upregulated in BC, directly binds to *CDKN1A* (p21), a well-known tumor-suppressive gene \[[@B29]\]. Moreover, *miR-125b* and *miR-200c* target the oncogene *E2F3*, which is critical for the G~1~/S transition and is overexpressed in most high-grade BCs \[[@B30][@B31]\]. Inoguchi et al. \[[@B32]\] found that *miR-24* regulates *FOXM1*, which is critical for mediating cell cycle progression proteins, such as *Aurora B*, *cyclin B1*, and *CDC25B*, and stimulates the expression of *SKP2/CKS1*, which is involved in the proteolysis of p27^kip1^ and in G~1~/S progression.

4. EMT-related genes as targets of miRNAs in BC
-----------------------------------------------

We also evaluated whether the expression of the different target genes could be validated in clinical BC samples ([Table 2](#T2){ref-type="table"}). The EMT is a key progression mechanism that is often activated during cancer invasion and metastasis and is characterized by loss of cell adhesion, repression of E cadherin expression, and increased cell mobility \[[@B33]\]. Members of the *miR-200* family are well-known regulators of the EMT in human malignancies, including BC \[[@B34]\], and some investigators have reported the functions of these miRNAs in BC \[[@B35][@B36]\].

FSCN1 and LASP1 are components of the filopodia and lamellipodia in various types of cells; both proteins are involved in mediating the dynamics of actin filaments and are activated during the EMT. *miR-133a* and *miR-145* directly regulate *FSCN1* \[[@B37]\], and the *miR-1/133a* cluster and *miR-218* regulate *LASP1* \[[@B38]\]. Restoration of the expression of these miRNAs accelerates cell migration and invasion activity *in vitro* \[[@B37][@B38]\]. Matrix metalloproteinases (MMPs) are calcium-dependent zinc-containing endopeptidases that are capable of degrading various extracellular matrix proteins. MMPs are involved in the cleavage of cell surface receptors, the release of apoptotic ligands (such as the FAS ligand), and chemokine/cytokine inactivation. MMPs are also thought to facilitate tumor cell invasion and metastasis via the degradation of the extracellular matrix. Transforming growth factor beta1 reduces the expression level of *miR-200b*, which directly regulates *MMP16*. This then activates other MMPs (e.g., MMP-2 and MMP-9), growth factors, and receptors, thereby facilitating local cellular mechanisms that promote migration \[[@B39]\].

Loss of expression of *miR-23b*, *miR-138*, and *miR-200c* (an *miR-200* family member) is associated with increased expression of *ZEB1*, *ZEB2*, and *ERFFI1*, which facilitate the progression of the EMT \[[@B36][@B40][@B41]\]. *ZEB1* and *ZEB2* are known to negatively regulate E cadherin expression and are directly targeted by *miR-23b* and *miR-138*, whereas *ERRFI-1*, a regulator of *EGFR*, is directly targeted by members of the *miR-200* family \[[@B36]\]. *ZEB1* expression has been reported in 22% of clinical BC tissue specimens, but is absent from the bladder mucosa \[[@B42]\]. Expression of the *miR-200* family has been shown to be repressed by hypermethylation of its promoter region, and loss of *miR-200c* expression is significantly associated with subsequent disease progression to MIBC and poor outcomes \[[@B35]\]. These studies implied that many EMT-related genes are activated through downregulation of several TS-miRNAs, and these phenomena may contribute to tumor progression of BC.

5. Others
---------

Downregulated miRNAs have also been reported to target some genes related to cytokine--cytokine receptor interactions, including *EGFR* (*miR-23b*, *miR-27b*, *miR-133a*, *miR-133b*) \[[@B24][@B43]\], *IGF1R* (*miR-145*) \[[@B44]\], and *MET* (*miR-23b*, *miR-27b*, *miR-101*) \[[@B24][@B43]\]. Activation of these genes may affect downstream cancer pathways, such as mammalian target of rapamycin signaling, phosphoinositol 3-kinase (PI3K)-Akt signaling, and mitogen-activated protein kinase (MAPK) signaling. *FGFR3*, which belongs to the MAPK signaling pathway, is crucial for BC oncogenesis, and mutations in *FGFR3* have been shown to accelerate proliferation in BC \[[@B45]\]. Downregulation of *miR-99a* and *miR-100* has been shown to cause upregulation of *FGFR3* expression before its mutation, which suggests that the acquisition of mutations may result from increased cell turnover \[[@B46]\]. The expression of *AKT1* and *ILK*, which are involved in the AKT-PI3K pathway, was shown to be repressed by the *miR-143/145* cluster, and proliferation is inhibited in cells transfected with these miRNAs \[[@B47][@B48]\]. The vascular endothelial growth factor (VEGF) and WNT signaling pathways are also important for BC development, and *VEGFC*, *FZD4*, *PSEN1*, and *WNT1* have been reported to be under the control of several TS-miRNAs \[[@B17][@B49][@B50][@B51][@B52]\].

MICRORNAS AS TUMOR MARKERS IN BLADDER CANCER
============================================

1. miRNAs as diagnostic markers for BC detection
------------------------------------------------

Many studies have investigated miRNA expression by quantitative real-time PCR of clinical BC specimens \[[@B20]\]. In this review, we focus on studies in which the investigators evaluated diagnostic accuracy by use of receiver-operator curve analyses of the sensitivity and specificity of specific miRNAs in comparison with normal bladder epithelium. We found 18 studies that satisfied our criteria ([Table 3](#T3){ref-type="table"}). In 2009, Ichimi et al. \[[@B19]\] first evaluated the expression of six miRNAs in tissues as diagnostic markers to distinguish BC (n=104) from non-BC (n=31).

There is a pressing need for highly accurate, noninvasive tests for BC diagnosis. The standard procedures for BC diagnosis and the follow-up for patients depend on urinary cytology and cystoscopy. Urinary cytology is a reliable urine marker for BC diagnosis because of its high specificity (90%--95%). However, this method has low sensitivity (30%--40%), and patients are forced to undergo a painful cystoscopic procedure to confirm the diagnosis. A number of noninvasive urine tests, such as bladder tumor antigen and NMP22, have been developed; however, their diagnostic specificities are inferior to that of urinary cytology tests, and these methods have failed to meet clinical expectations. Therefore, quantitative changes in miRNAs in urine, blood, and tissues are the primary focus in the search for new markers. miRNAs are detectable in urine with pelleted or cell-free urine samples. Hanke et al. \[[@B53]\] evaluated *miR-126* expression in whole urine samples and showed that this miRNA had a sensitivity of 72% and specificity of 82% when used as a diagnostic marker, even though the sample size in their study was small. Yamada et al. \[[@B54]\] also found that *miR-96* detection in the urine including the pellet was a useful diagnostic marker, with a sensitivity of 71.8% and a specificity of 89.2%. Shimizu et al. \[[@B55]\] uniquely reported good sensitivity of 81% and good specificity of 89% by testing a methylation panel of *miR-9-3*/*miR-124-2*/*miR-124-3*/*miR-137*. In terms of miRNA detection in cell-free urine \[[@B56][@B57][@B58][@B59][@B60]\], several studies have shown that this method provides moderate sensitivity and specificity for distinguishing BC from non-BC but that the results are inferior to those from studies using whole urine samples \[[@B53][@B54][@B55][@B61][@B62]\]. In blood tests, Jiang et al. \[[@B63]\] showed dramatic results (sensitivity of 90% and specificity of 90%) using a panel study of *miR-15b-5p*/*miR-27a-3p*/*miR-30a-5p*/*miR-148b-3p*/*miR-152*/*miR-3187-3p*.

2. miRNAs for predicting prognosis in patients with BC
------------------------------------------------------

Many retrospective studies have suggested that the expression of specific miRNAs in BC specimens may be a good prognostic marker predicting overall survival, disease-free survival, recurrence-free survival, or progression-free survival, as outlined in [Table 4](#T4){ref-type="table"}. Moreover, several reports analyzing urine and blood samples have shown that *miR-200*, *miR-214*, and *miR-3187-3p* levels are good prognostic markers in the blood \[[@B57][@B60][@B63][@B64]\]. Surprisingly, *miR-203*, *miR-214*, *miR-152*, and *miR-3187-3p* were shown to be independent markers predicting overall survival, progression-free survival, or recurrence-free survival in multivariate studies \[[@B63][@B64][@B65]\]. Unfortunately, no prospective studies have been performed to date. Thus, additional large, prospective studies are needed for the clinical application of miRNA assays for diagnostic and prognostic purposes in BC.

MICRORNAS AS A TREATMENT MODALITY IN BLADDER CANCER
===================================================

Some TS-miRNAs have been transfected into BC cell lines by using plasmid/virus vectors, followed by subcutaneous injection of the transfected cells into nude mice \[[@B27][@B66][@B67]\]. Significant inhibition of tumor growth \[[@B27][@B67]\] and metastasis \[[@B66]\] was observed. Yu et al. \[[@B66]\] found that the *CD44* gene was a direct target of *miR-34a* and that the pro-apoptotic role of *miR-34a* may be mediated primarily through regulation of CD44, which functions to promote metastasis and angiogenesis. Xu et al. \[[@B68]\] demonstrated that *miR-100*-transfected BC cells exhibited significant growth inhibition in an intravesical orthotopic BC model. In terms of onco-miRNAs, *miR-10b-* and *miR-155*-transfected BC xenografts exhibited significantly increased growth in comparison with controls \[[@B69][@B70]\]. Inamoto et al. \[[@B71]\] tested the anticancer effects of intravesical injection of *miR-145* by using cationic liposomes (Lipofectamine RNAiMAX, Thermo Fisher Scientific, Waltham, MA, USA) in an intravesical orthotopic BC model. They achieved adequate anticancer effects after intravesical administration of *miR-145*. These miRNAs are promising candidate miRNAs that may be useful for clinical applications in the future.

FUTURE PERSPECTIVES
===================

Many studies have examined the roles of miRNAs in human malignancies, including BC. However, the majority of miRNA studies have focused on candidate gene approaches with limited whole-genome sequencing, and a detailed characterization of miRNA profiles based on the genomic features of BC has not been reported. Recently, DS technology has been applied for profiling of mRNA and miRNA in human cancers, including BC. However, DS technology has mainly focused on BC tissues without any particular selection according to clinical treatment. Additional DS analyses should be conducted using samples from patients who have undergone different treatments, e.g., chemotherapy regimens, radiation therapies, or immune-checkpoint drugs.

A growing body of evidence has shown that miRNAs have great potential for clinical use as new diagnostic biomarkers. However, detection of single miRNAs in urine samples will not be superior to current urinary cytology tests because of the relatively low diagnostic specificity of such analyses. Some recent studies have attempted to improve the diagnostic specificity of miRNA detection by using a panel of multiple miRNAs \[[@B55][@B56][@B61][@B63]\]. It will be important to select optimal combinations of miRNAs and to perform prospective translational studies in outpatients to validate such miRNA panels.

Moreover, recent studies have shown that some miRNAs control the activity of major cancer-related signaling molecules. Thus, identification of aberrant miRNA expression and oncogenic or tumor-suppressive molecular targets of miRNAs is necessary for the clinical development of novel cancer therapeutics. Because many TS-miRNAs and their target oncogenes are components of complex molecular networks, treatment with multiple miRNAs may provide stronger anticancer effects than treatment with a single miRNA. In an interesting study by Liu et al. \[[@B72]\], new vectors, termed \"miRNA-mowers,\" that contained the entire sequence of the onco-*miR-183-96-182* cluster were constructed. Transfection of the miRNA-mowers strongly inhibited cell growth and migration and induced apoptosis *in vitro*, suggesting the usefulness of targeting multiple onco-miRNAs. However, no studies have yet reported successful results for intravenous administration of TS-miRNAs in the induction of anticancer effects *in vivo*. The development of an adequate drug delivery system for TS-miRNAs is needed; otherwise, it will be difficult to determine the value of miRNAs as a therapeutic modality.
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###### miRNAs and their target genes validated by lusiferase reporter assay
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  miRNAs          Stem-loop sequence   Locus              Clustered miRNAs                                 miRNA type   Target    Reference
  --------------- -------------------- ------------------ ------------------------------------------------ ------------ --------- -----------
  miR-1           miR-1-1              20q13              ND                                               TS           LASP1     [@B38]
  miR-1-2         18q11                miR-133a-1         PNP                                              [@B73]                 
  PTMA            [@B73]                                                                                                          
  SRSF9           [@B26]                                                                                                          
  TAGLN2          [@B74]                                                                                                          
  miR-16          miR-16-1             13q14              miR-15a                                          TS           CCND1     [@B75]
  miR-16-2        3q25                 miR-15b                                                                                    
  miR-23b         miR-23b              9q22               miR-27b                                          TS           EGFR      [@B24]
  miR-3074        MET                  [@B24]                                                                                     
  miR-24-1        ZEB1                 [@B40]                                                                                     
  miR-24          miR-24-1             9q22               miR-23b, miR-27b, miR-3074                       TS           CARD10    [@B76]
  miR-24-2        19p13                miR-23a, miR-27a   FOXM1                                            [@B32]                 
  miR-27a         miR-27a              19p13              miR-23a, miR-24-2                                TS           RUNX1     [@B77]
  SLC7A11         [@B78]                                                                                                          
  miR-27b         miR-27b              9q22               miR-23b, miR-24-1, miR-3074                      TS           DROSHA    [@B79]
  EGFR            [@B24]                                                                                                          
  MET             [@B24]                                                                                                          
  miR-29c         miR-29c              1q32               miR-29b-2                                        TS           CDK6      [@B80]
  miR-30a         miR-30a              6q13               ND                                               TS           NOTCH1    [@B81]
  miR-34a         miR-34a              1p36               ND                                               TS           CD44      [@B66]
  HNF4G           [@B82]                                                                                                          
  NOTCH1          [@B83]                                                                                                          
  miR-99a         miR-99a              21q21              let-7c                                           TS           FGFR3     [@B46]
  miR-100         miR-100              11q24              ND                                               TS           MTOR      [@B68]
  miR-101         miR-101-1            1p31               miR-3671                                         TS           COX2      [@B84]
  miR-101-2       9p24                 ND                 MET                                              [@B85]                 
  VEGFC           [@B52]                                                                                                          
  miR-124-3p      miR-124              20q13              ND                                               TS           ROCK1     [@B86]
  CDK4            [@B87]                                                                                                          
  miR-125b        miR-125b-1           11q24              ND                                               TS           E2F3      [@B31]
  miR-125b-2      21q21                ND                 MMP13                                            [@B99]                 
  SPHK1           [@B89]                                                                                                          
  miR-128         miR-128-1            2q21               ND                                               TS           VEGFC     [@B49]
  miR-128-2       3p22                 ND                                                                                         
  miR-129         miR-129-1            7q32               ND                                               TS           GALNT1    [@B25]
  miR-129-2       11p11                ND                 SOX4                                                                    
  miR-133a        miR-133a-1           18q11              miR-1-2                                          TS           EGFR      [@B43]
  miR-133a-2      20q13                ND                 FSCN1                                            [@B37]                 
  GSTP1           [@B90]                                                                                                          
  LASP1           [@B38]                                                                                                          
  PNP             [@B73]                                                                                                          
  PTMA            [@B73]                                                                                                          
  TAGLN2          [@B74]                                                                                                          
  miR-133b        miR-133b             6p12               miR-206                                          TS           AKT1      [@B47]
  BCL2L2          [@B47]                                                                                                          
  EGFR            [@B43]                                                                                                          
  miR-135a        miR-135a-1           3p21               ND                                               TS           FOXO1     [@B91]
  miR-135a-2      12q23                ND                                                                                         
  miR-138         miR-138-1            3p21               ND                                               TS           ZEB2      [@B41]
  miR-138-2       16q13                ND                                                                                         
  miR-143         miR-143              5q32               miR-145                                          TS           SERPIN1   [@B22]
  AKT             [@B48]                                                                                                          
  miR-144-5p/3p   miR-144              17q11              miR-451a, miR-451b, miR-4732                     TS           CCNE1     [@B28]
  CCNE2                                                                                                                           
  CDC25A                                                                                                                          
  PKMYT1                                                                                                                          
  miR-145         miR-145              5q32               miR-143                                          TS           CBFB      [@B92]
  CLINT1          [@B92]                                                                                                          
  FSCN1           [@B37]                                                                                                          
  ILK             [@B48]                                                                                                          
  PAK1            [@B93]                                                                                                          
  PPP3CA          [@B92]                                                                                                          
  SERPIN1         [@B22]                                                                                                          
  SOCS7           [@B94]                                                                                                          
  IGF1R           [@B44]                                                                                                          
  miR-186         miR-186              1p31               ND                                               TS           HMGN5     [@B95]
  miR-193a-3p     miR-193a             17q11              ND                                               TS           LOXL4     [@B96]
  PSEN1           [@B52]                                                                                                          
  HOXC9           [@B97]                                                                                                          
  miR-195         miR-195              17p13              miR-497                                          TS           BIRC5     [@B17]
  CDC42           [@B98]                                                                                                          
  CDK4            [@B99]                                                                                                          
  GLUT3           [@B100]                                                                                                         
  WNT7A           [@B17]                                                                                                          
  miR-200b        miR-200b             1p36               miR-200a, miR-429                                TS           MMP16     [@B39]
  miR-200c        miR-200c             12p13              miR-141                                          TS           BMI1      [@B30]
  E2F3                                                                                                                            
  miR-203         miR-203              14q32              miR-203b                                         TS           BCL2L2    [@B65]
  BIRC5                                                                                                                           
  miR-214         miR-214              1q24               miR-199a-2, miR-3120                             TS           PDRG1     [@B101]
  miR-218         miR-218-1            4p15               ND                                               TS           BMI1      [@B67]
  miR-218-2       5q34                 ND                 LASP1                                            [@B38]                 
  miR-221         miR-221              Xp11               miR-222                                          TS           STMN1     [@B102]
  miR-320a        miR-320a             8p21               ND                                               TS           ITGB3     [@B103]
  miR-320c        miR-320c             18q11              ND                                               TS           CDK6      [@B104]
  miR-449a        miR-449a             5q11.2             miR-449b, miR-449c                               TS           CDC25A    [@B105]
  miR-485-5p      miR-485              14q32              ND                                               TS           HMGA2     [@B106]
  miR-490-5p      miR-490              7q33               ND                                               TS           FOS       [@B107]
  miR-493         miR-493              14q32              miR-337, miR-665                                 TS           FZD4      [@B51]
  RHOC                                                                                                                            
  miR-497         miR-497              17p13              miR-195                                          TS           BIRC5     [@B17]
  WNT7A                                                                                                                           
  miR-574-3p      miR-574              4p14               ND                                               TS           MESDC1    [@B108]
  miR-576-3p      miR-576              4q25               ND                                               TS           CCND1     [@B109]
  miR-590-3p      miR-590              7q11               ND                                               TS           TFAM      [@B110]
  miR-1182        miR-1182             1q42               ND                                               TS           TERT      [@B111]
  miR-9           miR-9-1              1q22               ND                                               Onco         CBX7      [@B112]
  miR-9-2         5q14                 ND                                                                                         
  miR-9-3         15q26                ND                 CERS2                                            [@B113]                
  miR-10b         miR-10b              2q31               ND                                               Onco         HOXD10    [@B70]
  KLF4                                                                                                                            
  miR-19a         miR-19a              13q31              miR-17, miR-18a, miR-20a, miR-19b-1, miR-92a-1   Onco         PTEN      [@B114]
  miR-96          miR-96               7q32               miR-18, miR-183                                  Onco         CDKN1A    [@B29]
  miR-150         miR-150              19q13              ND                                               Onco         PDCD4     [@B115]
  miR-155         miR-155              21q21              ND                                               Onco         DMTF1     [@B69]
  miR-182-5p      miR-182              7q32               ND                                               Onco         RECK      [@B116]
  SMAD4                                                                                                                           
  miR-708         miR-708              11q14              ND                                               Onco         CASP2     [@B27]

miRNA, microRNA; TS, tumor suppressive miRNA; Onco, oncogenic miRNA; ND, not determined.

###### Functional annotation of the target genes and the relative miRNAs

![](icu-57-S60-i002)

  Annotation                                 Target                      miRNA                                  miRNA type   Target validation in clinical BCs   Reference
  ------------------------------------------ --------------------------- -------------------------------------- ------------ ----------------------------------- ----------------
  Apoptosis                                  BCL2L2                      miR-133b, miR-203                      TS           yes                                 [@B47],[@B65]
  BIRC5                                      miR-195, miR-203, miR-497   TS                                     yes          [@B17],[@B65]                       
  BMI1                                       miR-200c, miR-218           TS                                     no           [@B30],[@B67]                       
  CASP2                                      miR-708                     Onco                                   yes          [@B27]                              
  SOCS7                                      miR-145                     TS                                     no           [@B94]                              
  SOX4                                       miR-129                     TS                                     yes          [@B25]                              
  SRSF9                                      miR-1                       TS                                     yes          [@B26]                              
  Cell cycle                                 CCND1                       miR-16, miR-576-3p                     TS           yes                                 [@B75],[@B109]
  CCNE1                                      miR-144-5p/3p               TS                                     yes          [@B28]                              
  CCNE2                                      miR-144-5p/3p               TS                                     yes          [@B28]                              
  CDC25A                                     miR-144-5p/3p               TS                                     yes          [@B28]                              
  CDC25A                                     miR-449a                    TS                                     yes          [@B105]                             
  CDK4                                       miR-124-3p                  TS                                     no           [@B87]                              
  CDK4                                       miR-195                     TS                                     yes          [@B99]                              
  CDK6                                       miR-29c, miR-320c           TS                                     yes          [@B80],[@B104]                      
  CDK6                                       miR-449a                    TS                                     yes          [@B105]                             
  CDKN1A                                     miR-96                      Onco                                   yes          [@B29]                              
  E2F3                                       MiR-125b, miR-200c          TS                                     yes          [@B30],[@B31]                       
  FOXM1                                      miR-24                      TS                                     yes          [@B32]                              
  PKMYT1                                     miR-144-5p/3p               TS                                     yes          [@B28]                              
  STMN1                                      miR-221                     TS                                     no           [@B102]                             
  EMT                                        CARD10                      miR-24                                 TS           no                                  [@B76]
  CBX7                                       miR-9                       Onco                                   yes          [@B112]                             
  FSCN1                                      miR-133a                    TS                                     yes          [@B37]                              
  FSCN1                                      miR-145                     TS                                     yes          [@B37]                              
  HMGA2                                      miR-485-5p                  TS                                     no           [@B106]                             
  HMGN5                                      miR-186                     TS                                     yes          [@B95]                              
  LASP1                                      miR-1, miR-133a, miR-218    TS                                     yes          [@B38]                              
  LOXL4                                      miR-193a-3p                 TS                                     no           [@B96]                              
  MESDC1                                     miR-574-3p                  TS                                     no           [@B108]                             
  MMP13                                      MiR-125b                    TS                                     no           [@B88]                              
  MMP16                                      miR-200b                    TS                                     no           [@B39]                              
  ZEB1                                       miR-23b                     TS                                     yes          [@B40]                              
  ZEB2                                       miR-138                     TS                                     yes          [@B41]                              
  Cytokaine-cytokaine receptor intaraction   EGFR                        miR-23b, miR-27b, miR-133a, miR-133b   TS           yes                                 [@B24],[@B85]
  IGF1R                                      miR-145                     TS                                     no           [@B44]                              
  MET                                        miR-23b, miR-27b, miR-101   TS                                     yes          [@B24],[@B85]                       
  MAPK signaling                             FGFR3                       miR-99a, miR-100                       TS           yes                                 [@B46]
  FOS                                        miR-490-5p                  TS                                     yes          [@B108]                             
  RECK                                       miR-182-5p                  Onco                                   yes          [@B116]                             
  Notch signaling                            NOTCH1                      miR-30a, miR-34a                       TS           yes                                 [@B81],[@B83]
  PI3K-Akt signaling                         AKT1                        miR-133b                               TS           yes                                 [@B47]
  AKT1                                       miR-143                     TS                                     no           [@B48]                              
  ILK                                        miR-145                     TS                                     no           [@B48]                              
  MTOR                                       miR-100                     TS                                     yes          [@B68]                              
  PTEN                                       miR-19a                     Onco                                   no           [@B114]                             
  Ras signaling                              CDC42                       miR-195                                TS           yes                                 [@B98]
  PAK1                                       miR-145                     TS                                     no           [@B93]                              
  RHOC                                       miR-493                     TS                                     no           [@B51]                              
  ROCK1                                      miR-124-3p                  TS                                     yes          [@B86]                              
  VEGF signaling                             VEGFC                       miR-101                                TS           yes                                 [@B49],[@B52]
  WNT signaling                              FZD4                        miR-493                                TS           no                                  [@B51]
  PSEN1                                      miR-193a-3p                 TS                                     no           [@B52]                              
  WNT7A                                      miR-195, miR-497            TS                                     yes          [@B17]                              
  Metabolic                                  CERS2                       miR-9                                  Onco         yes                                 [@B113]
  COX2                                       miR-101                     TS                                     no           [@B84]                              
  GALNT1                                     miR-129                     TS                                     yes          [@B25]                              
  ECM-receptor                               CD44                        miR-34a                                TS           yes                                 [@B66]
  ITGB3                                      miR-320a                    TS                                     yes          [@B103]                             

miRNA, microRNA; TS, tumor suppressive miRNA; Onco, oncogenic miRNA; ND, not determined.

###### miRNAs as diagnostic markers

![](icu-57-S60-i003)

  Sample                   Study    Year                                                               Calculator                       BC/Cont. (n)   Sensitivity   Specificity   Reference
  ------------------------ -------- ------------------------------------------------------------------ -------------------------------- -------------- ------------- ------------- -----------
  Tissue                   Liu      2015                                                               miR-141                          30/30          78.2          51.6          [@B139]
  miR-200b                 81.3     47                                                                                                                                             
  Ichimi                   2009     miR-30a-3p                                                         104/31                           94.3           76.7          [@B19]        
  miR-125                  89.4     77.4                                                                                                                                           
  miR-133a                 93.3     77.4                                                                                                                                           
  miR-145                  90.5     77.4                                                                                                                                           
  miR-195                  91.4     80                                                                                                                                             
  miR-199a^\*^             72.1     90.3                                                                                                                                           
  Urine                    Long     2015                                                               miR-26a/miR-93/miR-191/miR-940   85/45          70            84            [@B56]
  Wang                     2015     miR-214                                                            192/169                          90.5           65.6          [@B57]        
  Zhang                    2014     miR-99a, miR-125b                                                  50                               86.7           81.1          [@B58]        
  Zhou                     2014     miR-106b                                                           112/78                           76.8           72.4          [@B59]        
  Tolle                    2013     miR-520e                                                           36/19                            70             63.2          [@B117]       
  miR-618                  70       68.4                                                                                                                                           
  miR-1255b-5p             85       68.4                                                                                                                                           
  Mengual                  2013     miR-18a^\*^/miR-25/miR-140-5p/miR-142-3p/miR-187/miR-204           151/126                          84.8           86.5          [@B61]        
  Shimizu                  2013     miR-9-3/miR-124-2/miR-124-3/miR-137                                86/20                            81             89            [@B55]        
  Yun                      2012     miR-145                                                            207/144                          77.8           61.1          [@B60]        
  Miah                     2012     miR-15b/miR-135b/miR-1224-3p                                       121/53                           94.1           51            [@B118]       
  Dudziec                  2011     miR-152/miR-328/miR-122-3p                                         68/53                            81             75            [@B62]        
  miR-212                  40       66                                                                                                                                             
  miR-328                  59       91                                                                                                                                             
  miR-1224-3p              84       58                                                                                                                                             
  Yamada                   2011     miR-96                                                             100/74                           71.8           89.2          [@B54]        
  miR-183                  74       77.3                                                                                                                                           
  Hanke                    2010     miR-126: miR-152 ratio                                             29/11                            72             82            [@B53]        
  miR-182: miR-152 ratio   55       82                                                                                                                                             
  Blood                    Motawi   2016                                                               miR-92a                          70/62          97.1          76.7          [@B119]
  miR-100                  90       66.7                                                                                                                                           
  miR-143                  78.6     93.3                                                                                                                                           
  Fang                     2015     miR-205                                                            89/56                            76.4           96.4          [@B120]       
  Du                       2015     miR-497/miR-663b                                                   109/115                          69.7           69.6          [@B121]       
  Jiang                    2015     miR-15b-5p/miR-27a-3p/miR-30a-5p/miR-148b-3p/miR-152/miR-3187-3p   110/110                          90             90            [@B63]        
  Tolle                    2013     miR-26b-5p                                                         38/20                            65             94.1          [@B117]       
  miR-144-5p               70       82.4                                                                                                                                           
  miR-374-5p               60       94.1                                                                                                                                           

miRNA, microRNA; BC, bladder cancer; Cont., control.

###### miRNAs as prognostic markers

![](icu-57-S60-i004)

  Sample       Study     Year                                    Calculator                  BC (n)              Valuables     Multivariate   Reference
  ------------ --------- --------------------------------------- --------------------------- ------------------- ------------- -------------- -----------
  Tissue       Zhang     2016                                    miR-30a                     50                  OS, RFS       N/A            [@B81]
  Xu           2015      let-7c, miR-99a, miR-125b-1, miR-193a   202                         OS                  N/A           [@B124]        
  Zhang        2015      miR-21                                  53                          OS                  N/A           [@B122]        
  Wang         2015      miR-141                                 114                         DSS                 N/A           [@B127]        
  Avgeris      2015      miR-143, miR-145                        133                         OS, PFS             N/A           [@B125]        
  Zhang        2015      miR-203                                 108                         OS, PFS             Independent   [@B65]         
  Wu           2015      miR-424                                 124                         OS, RFS             N/A           [@B123]        
  Segersten    2014      miR-10a-5p                              86                          PFS                 N/A           [@B129]        
  Lin          2014      miR-26a                                 126                         OS, DFS             N/A           [@B126]        
  Zhang        2014      miR-222                                 97                          OS                  N/A           [@B128]        
  Pignot       2013      miR-9, miR-182, miR-200b                166                         OS, RFS             N/A           [@B134]        
  Majid        2013      miR-23b                                 20                          OS                  N/A           [@B40]         
  Dyrskjot     2009      miR-29c, miR-129, miR-133b              106                         PFS                 N/A           [@B25]         
  Rosenberg    2013      miR-29c^\*^                             108                         PFS                 N/A           [@B132]        
  Wang         2013      miR-31                                  126                         OS, PFS             N/A           [@B131]        
  Ratert       2013      miR-141, miR-205                        40                          OS                  N/A           [@B130]        
  Pignot       2012      miR-19a, miR-20a, miR-92a               71                          OS                  N/A           [@B138]        
  Zaravinos    2012      miR-21                                  77                          OS                  N/A           [@B136]        
  Wang         2012      miR-100                                 126                         OS, PFS             N/A           [@B133]        
  Hirata       2012      miR-182-5p                              18                          OS                  N/A           [@B116]        
  Puerta-Gil   2012      miR-222, miR-143                        37                          OS, DSS, RFS, PFS   N/A           [@B137]        
  Majid        2012      miR-1280                                21                          OS                  N/A           [@B135]        
  Urine        Dudziec   2011                                    miR-152 CpG, miR-1224 CpG   68                  PFS           N/A            [@B62]
  Yun          2012      miR-200                                 138                         RFS                 N/A           [@B60]         
  Wang         2015      miR-214                                 192                         OS, RFS             N/A           [@B57]         
  Kim          2013      miR-214                                 138                         RFS                 Independent   [@B64]         
  Blood        Jiang     2015                                    miR-152, miR-3187-3p        110                 RFS           Independent    [@B63]
  Fang         2015      miR-205                                 89                          DSS                 N/A           [@B120]        

miRNA, microRNA; BC, bladder cancer; OS, overall survival; DSS, disease specific survival; PFS, progression free survival; RFS, recurrence free survival; N/A, not applicable.
